Business & Finance

Biopharma company reports second quarter results

Published in Cancer Weekly, March 8th, 2005

Myriad Genetics, Inc., (NASDAQ:MYGN) reported financial results for the second quarter of fiscal 2005 and the 6 months ended December 31, 2004.

For the second fiscal quarter, ended December 31, 2004, predictive medicine revenues grew to a record $17.5 million from $10.4 million for the same quarter last year, a $7.1 million, or 68% increase. Compared with the first fiscal quarter of 2005, predictive medicine revenues were up $3.1 million, or 22%.

The company believes that this significant increase in predictive medicine revenues resulted from strong customer demand for Myriad's predictive medicine products due in part to the increased clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-03-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry